http://rdf.ncbi.nlm.nih.gov/pubchem/patent/JP-2008501690-A
Outgoing Links
| Predicate | Object |
|---|---|
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D239-94 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-4709 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-517 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-517 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D405-04 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-4709 |
| filingDate | 2005-06-01-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationDate | 2008-01-24-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | JP-2008501690-A |
| titleOfInvention | How to treat cancer |
| abstract | The present invention relates to a method for treating cancer in mammals by administering 4-quinazolinamine and a pharmaceutical composition containing the same. In particular, the method is N- {3-chloro-4-[(3-fluorobenzyl) oxy] phenyl} -6- [5-({[2- (methanesulfonyl) ethyl] amino} methyl) -2-furyl ] -4-Quinazolinamine and salts and solvates thereof for the treatment of cancer mediated by tyrosine kinase EGFR and / or erbB2. [Selection figure] None |
| priorityDate | 2004-06-03-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 171.